Mandi Bishop, MA, CEO of Aloha Health, and Nicole Fisher, founder and CEO of HHR Strategies, discuss how the Affordable Care Act is woven into the fabric of American healthcare, provided some speculation on the new administration in the White House, and dove into Fisher's work on concussion legislation for youth sports and her involvement in the NFL concussion Congressional hearings.
In the latest Managed Care Cast, Mandi Bishop, MA, CEO of Aloha Health, discusses what goes into making health policy with Nicole Fisher, the founder and CEO of HHR Strategies and a Forbes contributor. Fisher is a senior policy advisor on Capitol Hill and has had a behind-the-scenes look into how policy is shaped.
Throughout the interview, Bishop and Fisher discuss how the Affordable Care Act is woven into the fabric of American healthcare, provided some speculation on the new administration in the White House, and dove into Fisher's work on concussion legislation for youth sports and her involvement in the NFL concussion Congressional hearings.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More